90 related articles for article (PubMed ID: 18976766)
1. Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women.
Yasui T; Uemura H; Hyodo S; Yamada M; Yamamoto S; Maegawa M; Tsuchiya N; Noguchi M; Yuzurihara M; Kase Y; Irahara M
Atherosclerosis; 2009 Jun; 204(2):471-5. PubMed ID: 18976766
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy.
Yasui T; Saijo A; Uemura H; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Eur J Endocrinol; 2009 Aug; 161(2):267-73. PubMed ID: 19451213
[TBL] [Abstract][Full Text] [Related]
3. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
4. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.
Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Vitoratos N; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC
Atherosclerosis; 2007 Jul; 193(1):142-50. PubMed ID: 16842799
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 is associated with monocyte chemoattractant protein-1 and soluble E-selectin levels in peripheral blood of newly post-menopausal women.
Yasui T; Saijo A; Uemura H; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
J Reprod Immunol; 2009 Jul; 81(1):97-102. PubMed ID: 19501916
[TBL] [Abstract][Full Text] [Related]
6. Effects of raloxifene treatment on the phenotype of blood monocytes.
Boudjeltia KZ; Durez P; Oberweis D; Guillaume M; Remacle C; Cauchie P; Vanhaeverbeek M; Brohée D; Ducobu J; Gregoir C
Can J Physiol Pharmacol; 2010 May; 88(5):601-5. PubMed ID: 20555430
[TBL] [Abstract][Full Text] [Related]
7. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
8. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
9. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
10. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
[TBL] [Abstract][Full Text] [Related]
11. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
[TBL] [Abstract][Full Text] [Related]
12. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
13. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
15. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Teerlink T; van der Mooren MJ
Fertil Steril; 2004 Dec; 82(6):1540-9. PubMed ID: 15589857
[TBL] [Abstract][Full Text] [Related]
16. Induction of circulating monocyte chemoattractant protein-1 in women with gonadotropin-releasing hormone agonist.
Matsui S; Yasui T; Uemura H; Yamamoto S; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
J Reprod Immunol; 2011 Aug; 90(2):227-34. PubMed ID: 21726903
[TBL] [Abstract][Full Text] [Related]
17. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
